Phase 2 Prostate Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who are able to give written consent and follow the study requirements
- People whose cancer can be measured using standard imaging criteria (known as RECIST v1.1)
- People with a confirmed diagnosis of small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), or neuroendocrine carcinoma originating outside the lungs (EP-NEC) that cannot be removed by surgery and has spread
- People with mixed tumour types may be eligible if the neuroendocrine or small cell component makes up at least 50% of the tumour tissue
- People with a specific type of slower-growing but aggressive neuroendocrine tumour (well differentiated grade 3, Ki-67 ≥ 55%) may be considered if their tumour tests positive for a protein called DLL3 (confirm with trial site)
- People who have already received standard treatments (such as platinum-based chemotherapy, with or without immunotherapy), or for whom standard treatment is unavailable or not tolerated
- Depending on which part of the trial a person is being considered for, different treatment history requirements apply — including first-line, second-line, or third-line treatment settings (confirm with trial site which sub-study may apply)
- People able to provide a tumour tissue sample (either a new biopsy or previously stored tissue) for laboratory testing
- People with a good general health and activity level, rated 0 or 1 on a standard medical scale (ECOG), meaning fully active or restricted in strenuous activity only
- People with adequate organ function confirmed through blood tests at the start of the study
Who may not be able to join:
- People whose neuroendocrine cancer developed as a transformation from a different type of lung cancer called non-small cell lung cancer (NSCLC)
- Women who are pregnant or currently breastfeeding
- Women who are capable of becoming pregnant and are not using adequate contraception
- People who have required systemic medical treatment for an autoimmune disease within the past 12 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 858-766-0852
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To determine recommended dose for expansion (RDE) of Peluntamig (PT217).; To evaluate the safety and tolerability of Peluntamig (PT217).; To evaluate the efficacy of Peluntamig (PT217) monotherapy or in combination treatments as assessed by ORR.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.